|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 81.95 HKD | -1.50% |
|
-8.44% | +7.41% |
| 01-12 | Innovent Biologics: a Rising Star in Biopharma |  |
| 12-31 | Wall Street Cues, Economic Outlooks Roil Asian Stock Markets | MT |
| Capitalization | 129B 144B 18.51B 15.77B 14.61B 13.74B 25.58B 1,684B 27.44B 169B 66.65B 801B 69.4B 67.98B 2,923B | P/E ratio 2025 * |
76.1x | P/E ratio 2026 * | 40x |
|---|---|---|---|---|---|
| Enterprise value | 119B 133B 17.1B 14.57B 13.5B 12.7B 23.63B 1,556B 25.35B 156B 61.56B 740B 64.11B 62.79B 2,700B | EV / Sales 2025 * |
9.05x | EV / Sales 2026 * | 6.73x |
| Free-Float |
93.21% | Yield 2025 * |
-
| Yield 2026 * | 0.02% |
Last Transcript: Innovent Biologics, Inc.
| 1 day | -1.56% | ||
| 1 week | -8.44% | ||
| Current month | +7.41% | ||
| 1 month | +0.12% | ||
| 3 months | -5.75% | ||
| 6 months | -7.61% | ||
| Current year | +7.41% |
| 1 week | 81.7 |  | 91.45 |
| 1 month | 76 | | 92.75 |
| Current year | 76.75 | | 92.75 |
| 1 year | 30.75 | | 109.1 |
| 3 years | 27.3 | | 109.1 |
| 5 years | 18.06 | | 109.1 |
| 10 years | 14 | | 109.1 |
| Manager | Title | Age | Since |
|---|---|---|---|
De Chao Yu
CEO | Chief Executive Officer | 62 | 2011-04-27 |
Fei You
DFI | Director of Finance/CFO | 47 | 2024-02-04 |
Ghang Shou Gao
CTO | Chief Tech/Sci/R&D Officer | - | 2020-10-31 |
| Director | Title | Age | Since |
|---|---|---|---|
De Chao Yu
CHM | Chairman | 62 | 2011-04-27 |
Charles Cooney
BRD | Director/Board Member | 81 | 2015-10-17 |
Hao Xi Ede
BRD | Director/Board Member | 67 | 2018-06-03 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.50% | -8.44% | +161.66% | +77.27% | 18.99B | |
| +0.10% | -3.31% | +7.66% | +1.63% | 75.21B | |
| -0.05% | +92.00% | +92.00% | +92.00% | 60.39B | |
| -0.75% | +1.12% | -35.83% | -41.20% | 57.13B | |
| -0.58% | +0.87% | +39.99% | +233.77% | 57.05B | |
| +0.58% | -7.25% | +17.67% | -42.13% | 24.12B | |
| -3.38% | -0.78% | +42.67% | +23.34% | 20.85B | |
| -3.02% | +0.73% | +51.02% | +1,314.71% | 18.01B | |
| +2.80% | +8.59% | +26.25% | -77.83% | 16.34B | |
| +1.22% | -2.43% | +128.44% | +815.66% | 14.7B | |
| Average | -0.46% | -1.04% | +53.15% | +239.72% | 36.28B | |
| Weighted average by Cap. | -0.40% | -1.14% | +38.55% | +143.32% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 13.14B 14.73B 1.89B 1.61B 1.49B 1.4B 2.61B 172B 2.8B 17.21B 6.8B 81.73B 7.08B 6.94B 298B | 17.29B 19.38B 2.48B 2.12B 1.96B 1.85B 3.44B 226B 3.68B 22.65B 8.95B 108B 9.32B 9.13B 392B |
| Net income | 1.66B 1.86B 239M 204M 189M 177M 330M 21.75B 354M 2.18B 860M 10.34B 896M 878M 37.74B | 3.19B 3.57B 458M 390M 362M 340M 633M 41.7B 679M 4.18B 1.65B 19.83B 1.72B 1.68B 72.36B |
| Net Debt | -9.82B -11B -1.41B -1.2B -1.11B -1.05B -1.95B -128B -2.09B -12.86B -5.08B -61.05B -5.29B -5.18B -223B | -12.37B -13.86B -1.78B -1.52B -1.4B -1.32B -2.46B -162B -2.64B -16.2B -6.4B -76.93B -6.67B -6.53B -281B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-01-20 | 81.95 $ | -1.50% | 5,363,841 |
| 26-01-20 | 83.20 $ | -2.52% | 9,115,621 |
| 26-01-19 | 85.35 $ | -4.64% | 14,220,210 |
| 26-01-16 | 89.50 $ | +0.56% | 6,745,760 |
| 26-01-15 | 89.00 $ | -0.50% | 11,496,890 |
Delayed Quote Hong Kong S.E., January 20, 2026 at 10:39 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 1801 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition